The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Senator Launches Probe into 5 Top Opioid Drugmakers

U.S. Senator Launches Probe into 5 Top Opioid Drugmakers

March 29, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—U.S. Democratic Senator Claire McCaskill sought on Tuesday details from the nation’s top opioid drugmakers on their sales and marketing practices, as lawmakers step up efforts to tackle the country’s deadly opioid crisis.

You Might Also Like
  • U.S. Senator Expands Opioid Probe to Distributors, Drugmakers
  • U.S. Senators Question Kaleo’s $4,500 tag on Opioid Overdose Treatment
  • U.S. Senator Reveals Results of Opioid Inquiry into Insys

The Missouri senator’s investigation comes amid an epidemic of opioid addiction, with 91 Americans dying everyday as a result of overdose, according to the U.S. Centers for Disease Control and Prevention.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“This epidemic is the direct result of a calculated sales and marketing strategy major opioid manufacturers have allegedly pursued over the past 20 years to expand their market share,” McCaskill, the top Democrat on the Senate Homeland Security and Governmental Affairs Committee, wrote in a letter to the drugmakers. (http://bit.ly/2o7pa4p)

McCaskill asked Johnson & Johnson, Mylan NV, Purdue Pharma, Insys Therapeutics Inc and Depomed Inc for internal estimates of the risk of abuse, addiction and overdose of opioids.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The companies are the top five U.S. prescription opioid drugmakers by 2015 sales, according to McCaskill’s letter.

Depomed and Purdue Pharma said they were reviewing the letter and would respond accordingly.

Purdue also said its OxyContin painkiller made up just 2 percent of the U.S. opioid analgesic prescription market.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Johnson & Johnson said it had received the letter and would address the senator’s request.

“We believe that we have acted appropriately, responsibly and in the best interests of patients regarding our opioid pain medications,” said Jessica Castles Smith, a spokeswoman for Johnson & Johnson unit Janssen.

Mylan said it is committed to helping find solutions to the issue of opioid abuse and misuse.

“We welcome the senator’s interest in this important matter and we share her concerns regarding the misuse of prescription opioids,” a Mylan spokeswoman told Reuters in an email.

Filed Under: Drug Updates, Professional Topics Tagged With: Depomed Inc, epidemic, Insys Therapeutics Inc, Johnson & Johnson, Mylan NV, opioid crisis, Opioid drugmaker probe, Purdue Pharma, sales and marketing practices, U.S. Democratic Senator Claire McCaskill

You Might Also Like:
  • U.S. Senator Expands Opioid Probe to Distributors, Drugmakers
  • U.S. Senators Question Kaleo’s $4,500 tag on Opioid Overdose Treatment
  • U.S. Senator Reveals Results of Opioid Inquiry into Insys
  • U.S. Launches Opioid Fraud and Detection Unit

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.